Amy Austin
Family · Morristown, TNNPI 1861821449
Payments from drug & device makers
Across 389 payments — averaging $38.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$11K
- Novo Nordisk$1K
- GSK$578
- AstraZeneca$276
- Novartis$272
- Pfizer$189
- plus $1K from 33 others
What the payments were for
- Speaking & faculty fees$9,95066%
- Travel & lodging$2722%
- Food & beverage$4,89632%
- Education$70%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 88 | $11,308 |
| Novo Nordisk | 102 | $1,034 |
| GSK | 77 | $578 |
| AstraZeneca | 13 | $276 |
| Novartis | 14 | $272 |
| Pfizer | 12 | $189 |
| Astellas Pharma US Inc | 9 | $154 |
| Amgen | 9 | $141 |
| Silk Road Medical, Inc. | 1 | $98 |
| Dexcom, Inc. | 6 | $94 |
| Johnson & Johnson | 6 | $91 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $84 |
| Lundbeck LLC | 4 | $77 |
| Sanofi-aventis U.S. LLC | 5 | $77 |
| Arbor Pharmaceuticals, Inc. | 4 | $63 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $58 |
| Merz North America, Inc. | 2 | $50 |
| Edwards Lifesciences | 2 | $44 |
| Lilly USA, LLC | 3 | $43 |
| Eisai Inc. | 2 | $42 |
| Boehringer Ingelheim | 3 | $37 |
| Esperion Therapeutics, Inc. | 2 | $33 |
| Daiichi Sankyo Inc. | 1 | $19 |
| Antares Pharma, Inc. | 1 | $19 |
| Axsome Therapeutics, Inc. | 1 | $19 |
| Revance Therapeutics, Inc. | 1 | $19 |
| Ardelyx, Inc. | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $18 |
| Vertex | 1 | $18 |
| Abiomed | 1 | $17 |
| Mylan Specialty L.p. | 1 | $17 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Azurity Pharmaceuticals, Inc. | 1 | $16 |
| Biohaven Pharmaceuticals, Inc. | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Xeris Pharmaceuticals, Inc. | 1 | $14 |
| Philips North America LLC | 1 | $14 |
| Merck | 1 | $12 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,125 in reported general payments places this provider in the 95th percentile of 6,706 family providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 48 | $70,495 |
| EliquisApixaban | 45 | $46,926 |
| JanuviaSitagliptin Phosphate | 21 | $29,114 |
| WegovySemaglutide | 20 | $26,690 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 26 | $24,770 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $23,709 |
| FarxigaDapagliflozin Propanediol | 19 | $22,838 |
| XareltoRivaroxaban | 18 | $21,803 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 18 | $12,560 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 15 | $9,297 |
| Spiriva RespimatTiotropium Bromide | 12 | $7,339 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 15 | $2,712 |
| Solifenacin Succinate | 24 | $2,468 |
| Omeprazole | 98 | $2,205 |
| Celecoxib | 33 | $2,067 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Wegovy | $1,034 | $97,18568 claims |
| PfizerEliquis | $189 | $46,92645 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $578 | $36,26940 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $276 | $32,13534 claims |
| MerckJanuvia | $12 | $29,11421 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $77 | $24,77026 claims |
| Johnson & JohnsonXarelto | $91 | $21,80318 claims |
| Boehringer IngelheimSpiriva Respimat | $37 | $7,33912 claims |
| AbbVieSynthroid | $11,308 | $99611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,706 family providers in Tennessee.
Other family in Morristown
- Stacy BrownMt Juliet$719K
- Dana WebberKnoxville$499K
- Brandy BiedermanHixson$448K
- Cynthia MillerMurfreesboro$384K
- Tamera ThoenerNashville$254K
- April SwonerHermitage$246K
- Jennifer WilliamsNashville$213K
- Chantil JeffreysGermantown$195K
- Laura PorchCordova$148K
- Lori LankfordNashville$148K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.